+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Insulin Drugs Market in Brazil 2024-2028

  • PDF Icon

    Report

  • 142 Pages
  • December 2023
  • Region: Brazil
  • TechNavio
  • ID: 5550385
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The human insulin drugs market in Brazil is forecasted to grow by USD 181.76 mn during 2023-2028, accelerating at a CAGR of 6.5% during the forecast period. The report on the human insulin drugs market in Brazil provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of diabetes in Brazil, demographic transition in Brazil, and increasing awareness of insulin therapy.

The human insulin drugs market in Brazil is segmented as below:

By Product

  • Basal insulin analog
  • NPH (Neutral Protamine Hagedorn)

By Application

  • Type I diabetes
  • Type II diabetes

By Distribution Channel

  • Retail
  • Hospitals
This study identifies the advent of biosimilars for treatment of diabetes as one of the prime reasons driving the human insulin drugs market in Brazil growth during the next few years. Also, increasing initiatives by vendors and technological advancements in human insulin drugs will lead to sizable demand in the market.

The report on the human insulin drugs market in Brazil covers the following areas:

  • Human insulin drugs market in Brazil sizing
  • Human insulin drugs market in Brazil forecast
  • Human insulin drugs market in Brazil industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in Brazil vendors that include Becton Dickinson and Co., Biocon Ltd., Biomm, Eli Lilly and Co., Empreendimentos Pague Menos SA, Gulf Pharmaceutical Industries, MannKind Corp., Medtronic Plc, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd.. Also, the human insulin drugs market in Brazil analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market Segmentation by Product
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 12: Chart on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibit 13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibit 14: Chart on Brazil: Year-over-year growth 2023-2028 (%)
Exhibit 15: Data Table on Brazil: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Human insulin drugs market in Brazil 2018 - 2022
Exhibit 16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 17: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Application Segment Analysis 2018 - 2022
Exhibit 18: Historic Market Size - Application Segment 2018 - 2022 ($ million)
4.4 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 27: Chart on Product - Market share 2023-2028 (%)
Exhibit 28: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 29: Chart on Comparison by Product
Exhibit 30: Data Table on Comparison by Product
6.3 Basal insulin analog - Market size and forecast 2023-2028
Exhibit 31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibit 32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibit 33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%)
Exhibit 34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%)
6.4 NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028
Exhibit 35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibit 37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
Exhibit 38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Product
Exhibit 39: Market opportunity by Product ($ million)
Exhibit 40: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Application
7.1 Market segments
Exhibit 41: Chart on Application - Market share 2023-2028 (%)
Exhibit 42: Data Table on Application - Market share 2023-2028 (%)
7.2 Comparison by Application
Exhibit 43: Chart on Comparison by Application
Exhibit 44: Data Table on Comparison by Application
7.3 Type I diabetes - Market size and forecast 2023-2028
Exhibit 45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibit 46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%)
Exhibit 48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%)
7.4 Type II diabetes - Market size and forecast 2023-2028
Exhibit 49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibit 51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%)
Exhibit 52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Application
Exhibit 53: Market opportunity by Application ($ million)
Exhibit 54: Data Table on Market opportunity by Application ($ million)
8 Market Segmentation by Distribution Channel
8.1 Market segments
Exhibit 55: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 56: Data Table on Distribution Channel - Market share 2023-2028 (%)
8.2 Comparison by Distribution Channel
Exhibit 57: Chart on Comparison by Distribution Channel
Exhibit 58: Data Table on Comparison by Distribution Channel
8.3 Retail - Market size and forecast 2023-2028
Exhibit 59: Chart on Retail - Market size and forecast 2023-2028 ($ million)
Exhibit 60: Data Table on Retail - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Chart on Retail - Year-over-year growth 2023-2028 (%)
Exhibit 62: Data Table on Retail - Year-over-year growth 2023-2028 (%)
8.4 Hospitals - Market size and forecast 2023-2028
Exhibit 63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibit 64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibit 65: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibit 66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
8.5 Market opportunity by Distribution Channel
Exhibit 67: Market opportunity by Distribution Channel ($ million)
Exhibit 68: Data Table on Market opportunity by Distribution Channel ($ million)
9 Customer Landscape
9.1 Customer landscape overview
Exhibit 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 70: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 71: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 72: Overview on factors of disruption
11.4 Industry risks
Exhibit 73: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 74: Vendors covered
12.2 Market positioning of vendors
Exhibit 75: Matrix on vendor position and classification
12.3 Becton Dickinson and Co.
Exhibit 76: Becton Dickinson and Co. - Overview
Exhibit 77: Becton Dickinson and Co. - Business segments
Exhibit 78: Becton Dickinson and Co. - Key news
Exhibit 79: Becton Dickinson and Co. - Key offerings
Exhibit 80: Becton Dickinson and Co. - Segment focus
12.4 Biocon Ltd.
Exhibit 81: Biocon Ltd. - Overview
Exhibit 82: Biocon Ltd. - Business segments
Exhibit 83: Biocon Ltd. - Key offerings
Exhibit 84: Biocon Ltd. - Segment focus
12.5 Biomm
Exhibit 85: Biomm - Overview
Exhibit 86: Biomm - Product / Service
Exhibit 87: Biomm - Key offerings
12.6 Eli Lilly and Co.
Exhibit 88: Eli Lilly and Co. - Overview
Exhibit 89: Eli Lilly and Co. - Product / Service
Exhibit 90: Eli Lilly and Co. - Key news
Exhibit 91: Eli Lilly and Co. - Key offerings
12.7 Empreendimentos Pague Menos SA
Exhibit 92: Empreendimentos Pague Menos SA - Overview
Exhibit 93: Empreendimentos Pague Menos SA - Product / Service
Exhibit 94: Empreendimentos Pague Menos SA - Key offerings
12.8 Gulf Pharmaceutical Industries
Exhibit 95: Gulf Pharmaceutical Industries - Overview
Exhibit 96: Gulf Pharmaceutical Industries - Product / Service
Exhibit 97: Gulf Pharmaceutical Industries - Key offerings
12.9 MannKind Corp.
Exhibit 98: MannKind Corp. - Overview
Exhibit 99: MannKind Corp. - Product / Service
Exhibit 100: MannKind Corp. - Key offerings
12.10 Medtronic Plc
Exhibit 101: Medtronic Plc - Overview
Exhibit 102: Medtronic Plc - Business segments
Exhibit 103: Medtronic Plc - Key news
Exhibit 104: Medtronic Plc - Key offerings
Exhibit 105: Medtronic Plc - Segment focus
12.11 Merck and Co. Inc.
Exhibit 106: Merck and Co. Inc. - Overview
Exhibit 107: Merck and Co. Inc. - Business segments
Exhibit 108: Merck and Co. Inc. - Key news
Exhibit 109: Merck and Co. Inc. - Key offerings
Exhibit 110: Merck and Co. Inc. - Segment focus
12.12 Novartis AG
Exhibit 111: Novartis AG - Overview
Exhibit 112: Novartis AG - Business segments
Exhibit 113: Novartis AG - Key offerings
Exhibit 114: Novartis AG - Segment focus
12.13 Novo Nordisk AS
Exhibit 115: Novo Nordisk AS - Overview
Exhibit 116: Novo Nordisk AS - Business segments
Exhibit 117: Novo Nordisk AS - Key offerings
Exhibit 118: Novo Nordisk AS - Segment focus
12.14 Sanofi SA
Exhibit 119: Sanofi SA - Overview
Exhibit 120: Sanofi SA - Business segments
Exhibit 121: Sanofi SA - Key news
Exhibit 122: Sanofi SA - Key offerings
Exhibit 123: Sanofi SA - Segment focus
12.15 Wockhardt Ltd.
Exhibit 124: Wockhardt Ltd. - Overview
Exhibit 125: Wockhardt Ltd. - Product / Service
Exhibit 126: Wockhardt Ltd. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 127: Inclusions checklist
Exhibit 128: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 129: Currency conversion rates for US$
13.4 Research methodology
Exhibit 130: Research methodology
Exhibit 131: Validation techniques employed for market sizing
Exhibit 132: Information sources
13.5 List of abbreviations
Exhibit 133: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Product
Exhibits 5: Executive Summary - Chart on Market Segmentation by Application
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Vendor Market Positioning
Exhibits 8: Parent market
Exhibits 9: Market Characteristics
Exhibits 10: Offerings of vendors included in the market definition
Exhibits 11: Market segments
Exhibits 12: Chart on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibits 13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibits 14: Chart on Brazil: Year-over-year growth 2023-2028 (%)
Exhibits 15: Data Table on Brazil: Year-over-year growth 2023-2028 (%)
Exhibits 16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million)
Exhibits 17: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits 18: Historic Market Size - Application Segment 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 20: Five forces analysis - Comparison between 2023 and 2028
Exhibits 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 23: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 24: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 25: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 26: Chart on Market condition - Five forces 2023 and 2028
Exhibits 27: Chart on Product - Market share 2023-2028 (%)
Exhibits 28: Data Table on Product - Market share 2023-2028 (%)
Exhibits 29: Chart on Comparison by Product
Exhibits 30: Data Table on Comparison by Product
Exhibits 31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibits 32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibits 33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%)
Exhibits 34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%)
Exhibits 35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibits 37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
Exhibits 38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
Exhibits 39: Market opportunity by Product ($ million)
Exhibits 40: Data Table on Market opportunity by Product ($ million)
Exhibits 41: Chart on Application - Market share 2023-2028 (%)
Exhibits 42: Data Table on Application - Market share 2023-2028 (%)
Exhibits 43: Chart on Comparison by Application
Exhibits 44: Data Table on Comparison by Application
Exhibits 45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits 46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits 47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%)
Exhibits 48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%)
Exhibits 49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits 51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%)
Exhibits 52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%)
Exhibits 53: Market opportunity by Application ($ million)
Exhibits 54: Data Table on Market opportunity by Application ($ million)
Exhibits 55: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 56: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 57: Chart on Comparison by Distribution Channel
Exhibits 58: Data Table on Comparison by Distribution Channel
Exhibits 59: Chart on Retail - Market size and forecast 2023-2028 ($ million)
Exhibits 60: Data Table on Retail - Market size and forecast 2023-2028 ($ million)
Exhibits 61: Chart on Retail - Year-over-year growth 2023-2028 (%)
Exhibits 62: Data Table on Retail - Year-over-year growth 2023-2028 (%)
Exhibits 63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibits 64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibits 65: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits 66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits 67: Market opportunity by Distribution Channel ($ million)
Exhibits 68: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 70: Impact of drivers and challenges in 2023 and 2028
Exhibits 71: Overview on Criticality of inputs and Factors of differentiation
Exhibits 72: Overview on factors of disruption
Exhibits 73: Impact of key risks on business
Exhibits 74: Vendors covered
Exhibits 75: Matrix on vendor position and classification
Exhibits 76: Becton Dickinson and Co. - Overview
Exhibits 77: Becton Dickinson and Co. - Business segments
Exhibits 78: Becton Dickinson and Co. - Key news
Exhibits 79: Becton Dickinson and Co. - Key offerings
Exhibits 80: Becton Dickinson and Co. - Segment focus
Exhibits 81: Biocon Ltd. - Overview
Exhibits 82: Biocon Ltd. - Business segments
Exhibits 83: Biocon Ltd. - Key offerings
Exhibits 84: Biocon Ltd. - Segment focus
Exhibits 85: Biomm - Overview
Exhibits 86: Biomm - Product / Service
Exhibits 87: Biomm - Key offerings
Exhibits 88: Eli Lilly and Co. - Overview
Exhibits 89: Eli Lilly and Co. - Product / Service
Exhibits 90: Eli Lilly and Co. - Key news
Exhibits 91: Eli Lilly and Co. - Key offerings
Exhibits 92: Empreendimentos Pague Menos SA - Overview
Exhibits 93: Empreendimentos Pague Menos SA - Product / Service
Exhibits 94: Empreendimentos Pague Menos SA - Key offerings
Exhibits 95: Gulf Pharmaceutical Industries - Overview
Exhibits 96: Gulf Pharmaceutical Industries - Product / Service
Exhibits 97: Gulf Pharmaceutical Industries - Key offerings
Exhibits 98: MannKind Corp. - Overview
Exhibits 99: MannKind Corp. - Product / Service
Exhibits 100: MannKind Corp. - Key offerings
Exhibits 101: Medtronic Plc - Overview
Exhibits 102: Medtronic Plc - Business segments
Exhibits 103: Medtronic Plc - Key news
Exhibits 104: Medtronic Plc - Key offerings
Exhibits 105: Medtronic Plc - Segment focus
Exhibits 106: Merck and Co. Inc. - Overview
Exhibits 107: Merck and Co. Inc. - Business segments
Exhibits 108: Merck and Co. Inc. - Key news
Exhibits 109: Merck and Co. Inc. - Key offerings
Exhibits 110: Merck and Co. Inc. - Segment focus
Exhibits 111: Novartis AG - Overview
Exhibits 112: Novartis AG - Business segments
Exhibits 113: Novartis AG - Key offerings
Exhibits 114: Novartis AG - Segment focus
Exhibits 115: Novo Nordisk AS - Overview
Exhibits 116: Novo Nordisk AS - Business segments
Exhibits 117: Novo Nordisk AS - Key offerings
Exhibits 118: Novo Nordisk AS - Segment focus
Exhibits 119: Sanofi SA - Overview
Exhibits 120: Sanofi SA - Business segments
Exhibits 121: Sanofi SA - Key news
Exhibits 122: Sanofi SA - Key offerings
Exhibits 123: Sanofi SA - Segment focus
Exhibits 124: Wockhardt Ltd. - Overview
Exhibits 125: Wockhardt Ltd. - Product / Service
Exhibits 126: Wockhardt Ltd. - Key offerings
Exhibits 127: Inclusions checklist
Exhibits 128: Exclusions checklist
Exhibits 129: Currency conversion rates for US$
Exhibits 130: Research methodology
Exhibits 131: Validation techniques employed for market sizing
Exhibits 132: Information sources
Exhibits 133: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the human insulin drugs market in Brazil: Becton Dickinson and Co., Biocon Ltd., Biomm, Eli Lilly and Co., Empreendimentos Pague Menos SA, Gulf Pharmaceutical Industries, MannKind Corp., Medtronic Plc, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advent of biosimilars for treatment of diabetes.'

According to the report, one of the major drivers for this market is the rising prevalence of diabetes in Brazil.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Becton Dickinson and Co.
  • Biocon Ltd.
  • Biomm
  • Eli Lilly and Co.
  • Empreendimentos Pague Menos SA
  • Gulf Pharmaceutical Industries
  • MannKind Corp.
  • Medtronic Plc
  • Merck and Co. Inc.
  • Novartis AG
  • Novo Nordisk AS
  • Sanofi SA
  • Wockhardt Ltd.